Archive

HIGHLIGHTS

 
LSP leads EUR 40 million Series C funding in iSTAR Medical
Amsterdam, the Netherlands — 5 September 2019: LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investm[...]
 
LSP leads €67m [$75m] Series A financing in Alizé Pharma 3
Significantly oversubscribed financing round with an LSP-led international syndicate of investors. Proceeds will be used to grow Alize Ph[...]
 
LSP joins as new investor in Nkarta Therapeutics in it's series B finanancing
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials   SOUTH SAN FRANCISCO, Cal[...]
 
LSP COMPANY NEWS
LSP portfolio company Binx Health to receive 510(k) marketing authorization for its io-system
 
LSP leads €116m [$133m] financing in AM-Pharma to Conduct Pivotal Phase III Trial...
Financing led by LSP and co-led by Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest [...]
 
LSP leads $38.5 Million Series B Financing in DNA Script
Oversubscribed round led by LSP will fund accelerated product development and commercial operations in the U.S.   Paris, May 16, 2019 — [...]
 
LSP leads € 28 million Series B financing in Imcyse
Imcyse raises a total of € 35 million in equity and grants and will use proceeds to facilitate clinical development of it’s technology in type [...]
 
Imcyse gives hope to patients with diabetes and MS
De Tijd - Biotech bedrijf Imcyse biedt hoop aan patiënten met diabetes en MS - Klik hier voor het artikel   De Tijd - Biotech company Im[...]
 
LSP portfolio company Pharvaris B.V. announced a $66 mln Series B round
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema   Pharva[...]
 
LSP co-leads $50 million Series A financing in SNIPR BIOME
Copenhagen, 11 March 2019 - SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announc[...]
 
LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics
LSP leads one of the largest initial financings for a European biotech company in a global syndicate supporting Arvelle to acquire exclusive rights[...]
 
LSP raises record €750 million in 10 months for life sciences innovations
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUT[...]
 
EMA making its first public appearance at our conference
The timing was perfect – the EMA would complete its move to Amsterdam in March and LSP would host its increasingly popular healthcare conference,[...]
 
LSP IN THE NEWS
LSP on BNR by Marco Groot (around Minute 3:00)
 

2019


Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist
SAN DIEGO, Sept. 18, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammat [...]
LSP portfolio company Pharvaris B.V. announced a $66 mln Series B round
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema   Pharvaris has initiated its first-in-human clinical trial of PHA121 Seri [...]
Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Es...
– Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose –   – Company Now Plans to Continue Study with All Three Dosing Arms – [...]
LSP joins as new investor in Nkarta Therapeutics in it's series B finanancing
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials   SOUTH SAN FRANCISCO, Calif. – September 4, 2019 – Nkarta Therapeutics, a privately-held bi [...]
LSP leads EUR 40 million Series C funding in iSTAR Medical
Amsterdam, the Netherlands — 5 September 2019: LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in iSTAR Medical SA, a Belgian private medical device company deve [...]
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion
Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to autograft Primary endpoint is radiographic interbody fusion at 12 months   Schlieren (Zurich), Switzerland, September 3, 2 [...]


2019
2018
2017
2016
2015
2014
2013
2012
back to news overview
Follow us

Archive

HIGHLIGHTS

 
LSP leads EUR 40 million Series C funding in iSTAR Medical
Amsterdam, the Netherlands — 5 September 2019: LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in iSTAR Medical SA, a Belgian private medical device company deve[...]
 
LSP leads €67m [$75m] Series A financing in Alizé Pharma 3
Significantly oversubscribed financing round with an LSP-led international syndicate of investors. Proceeds will be used to grow Alize Pharma 3’s team in Lyon and Boston, to advance its current programs in[...]
 
LSP joins as new investor in Nkarta Therapeutics in it's series B finanancing
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials   SOUTH SAN FRANCISCO, Calif. – September 4, 2019 – Nkarta Therapeutics, a privately-held bi[...]
 
LSP COMPANY NEWS
LSP portfolio company Binx Health to receive 510(k) marketing authorization for its io-system
 
LSP leads €116m [$133m] financing in AM-Pharma to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury
Financing led by LSP and co-led by Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare Proceeds to[...]
 
LSP leads $38.5 Million Series B Financing in DNA Script
Oversubscribed round led by LSP will fund accelerated product development and commercial operations in the U.S.   Paris, May 16, 2019 — DNA Script today announced an oversubscribed Series B fundraising of $[...]
 
LSP leads € 28 million Series B financing in Imcyse
Imcyse raises a total of € 35 million in equity and grants and will use proceeds to facilitate clinical development of it’s technology in type 1 diabetes, multiple sclerosis and other indications   Liège[...]
 
Imcyse gives hope to patients with diabetes and MS
De Tijd - Biotech bedrijf Imcyse biedt hoop aan patiënten met diabetes en MS - Klik hier voor het artikel   De Tijd - Biotech company Imcyse gives hope to patients with diabetes and MS - click here for th[...]
 
LSP portfolio company Pharvaris B.V. announced a $66 mln Series B round
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema   Pharvaris has initiated its first-in-human clinical trial of PHA121 Seri[...]
 
LSP co-leads $50 million Series A financing in SNIPR BIOME
Copenhagen, 11 March 2019 - SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announced a $50 million series A financing led by LSP and existing investor L[...]
 
LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics
LSP leads one of the largest initial financings for a European biotech company in a global syndicate supporting Arvelle to acquire exclusive rights from SK Biopharmaceuticals to develop and commercialize Cenobamate in[...]
 
LSP raises record €750 million in 10 months for life sciences innovations
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Succe[...]
 
EMA making its first public appearance at our conference
The timing was perfect – the EMA would complete its move to Amsterdam in March and LSP would host its increasingly popular healthcare conference, BioCapital Europe, in the same month. Having a representative from EM[...]
 
LSP IN THE NEWS
LSP on BNR by Marco Groot (around Minute 3:00)
 

2019


Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist
SAN DIEGO, Sept. 18, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammat [...]
LSP portfolio company Pharvaris B.V. announced a $66 mln Series B round
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema   Pharvaris has initiated its first-in-human clinical trial of PHA121 Seri [...]
Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis ...
– Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose –   – Company Now Plans to Continue Study with All Three Dosing Arms – [...]
LSP joins as new investor in Nkarta Therapeutics in it's series B finanancing
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials   SOUTH SAN FRANCISCO, Calif. – September 4, 2019 – Nkarta Therapeutics, a privately-held bi [...]
LSP leads EUR 40 million Series C funding in iSTAR Medical
Amsterdam, the Netherlands — 5 September 2019: LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in iSTAR Medical SA, a Belgian private medical device company deve [...]
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion
Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to autograft Primary endpoint is radiographic interbody fusion at 12 months   Schlieren (Zurich), Switzerland, September 3, 2 [...]


2019
2018
2017
2016
2015
2014
2013
2012
back to news overview